TSHA vs. NK, VXRT, ATHA, PASG, TCRR, IOVA, IMCR, TWST, VCEL, and ADMA
Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include NantKwest (NK), Vaxart (VXRT), Athira Pharma (ATHA), Passage Bio (PASG), TCR2 Therapeutics (TCRR), Iovance Biotherapeutics (IOVA), Immunocore (IMCR), Twist Bioscience (TWST), Vericel (VCEL), and ADMA Biologics (ADMA). These companies are all part of the "medical" sector.
NantKwest (NASDAQ:NK) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.
Taysha Gene Therapies has a consensus target price of $7.00, suggesting a potential upside of 104.08%. Given NantKwest's higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than NantKwest.
NantKwest has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.
In the previous week, Taysha Gene Therapies had 10 more articles in the media than NantKwest. MarketBeat recorded 10 mentions for Taysha Gene Therapies and 0 mentions for NantKwest. NantKwest's average media sentiment score of 0.16 beat Taysha Gene Therapies' score of 0.00 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.
NantKwest received 184 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 74.17% of users gave Taysha Gene Therapies an outperform vote while only 53.32% of users gave NantKwest an outperform vote.
9.4% of NantKwest shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 71.7% of NantKwest shares are held by insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
NantKwest has higher earnings, but lower revenue than Taysha Gene Therapies. NantKwest is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
Taysha Gene Therapies has a net margin of -833.60% compared to Taysha Gene Therapies' net margin of -76,658.58%. Taysha Gene Therapies' return on equity of -56.06% beat NantKwest's return on equity.
Summary
Taysha Gene Therapies beats NantKwest on 10 of the 17 factors compared between the two stocks.
Get Taysha Gene Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taysha Gene Therapies Competitors List
Related Companies and Tools
